Braincure Biotech Publishes Two New Reports
With more than 90 medicines in clinical trials or awaiting approval and knowledge of Alzheimer’s increasing, patients and caretakers look towards the future with high spirits.
Taipei, Taiwan, July 21, 2016 --(PR.com)-- Braincure Biotech has recently released two new studies at its annual Responsible Research Awards event which honors advancements in the field of research and care for individuals suffering from Alzheimer’s disease. The studies show how impediments play a fundamental role in the progress of Alzheimer’s research and also the current advancements that have been made towards tackling this complicated neurological condition.
“The biggest problem regarding Alzheimer’s is that it prohibits patients from fighting for themselves and therefor the responsibility for efficient solutions shifts completely towards medical research professionals,” said Dr. Armin Pietsch, Chairman and CEO of Braincure Biotech. “Counteracting this destructive neurological condition demands extended cooperation in the scientific, medical and patient treatment communities as well as a definite pledge from policymakers to back and appropriately reward medical advancements.”
The first study titled “Alzheimer’s: From Regress to Progress” has revealed that in the last decade up to 100 treatments and solutions have failed to be approved by medical authorities or to reach patients. During the same period there have been only three medicines that have been approved to treat Alzheimer’s symptoms, but not the conditions itself. This 30 to 1 ratio of setbacks to solutions indicates the problem with elaborating efficient solutions.
“The obstacles facing Alzheimer’s research are disappointing for both medical professionals as well as for the patients and their families; however these setbacks are a vital step forward towards better comprehending this problematic neurological condition,” said Dr. Pietsch. “The fact of the matter is that while we can regard these setbacks in the development of efficient Alzheimer’s solutions and treatments as failures they actually assist us in guiding research in the right direction by providing us with critical information that enable science to advance.”
As specified in “The Future of Alzheimer’s Treatment” study, companies in the biopharmaceutical and biotechnology research industries are actively examining and creating new medicines and technologies for patients affected by the disease and a number of other dementias, which includes among others a patent-pending device implanted in the omentum, a protective layer of skin that secures the abdominal organs which, once stimulated, has been confirmed to improve cognitive functions in the case of a number of degenerative neurological diseases.
“In order for such vital and innovative work to progress and to alleviate the expensive impact of this condition on our healthcare system, policymakers need to support approaches and policies that promote medical developments and embrace growth drivers like the biopharmaceutical and biotechnology sectors,” concluded Mr. Pietsch.
About Braincure Biotech
Braincure Biotech is an innovative company specialized in biotechnology as well as biopharmaceuticals, committed to pursuing the development of original treatment procedures with the aim of combating dementias, with an emphasis on Alzheimer’s disease. We possess one of the most extensive international pipelines for the treatment of Alzheimer’s and also a comprehensive strategy to product growth.
Address: Taipei Far Eastern Plaza, No. 207, Section 2, Dun Hua South Road, Taipei 106, Taiwan (R.O.C.).
contact@braincure-biotech.com
http://www.braincure-biotech.com
“The biggest problem regarding Alzheimer’s is that it prohibits patients from fighting for themselves and therefor the responsibility for efficient solutions shifts completely towards medical research professionals,” said Dr. Armin Pietsch, Chairman and CEO of Braincure Biotech. “Counteracting this destructive neurological condition demands extended cooperation in the scientific, medical and patient treatment communities as well as a definite pledge from policymakers to back and appropriately reward medical advancements.”
The first study titled “Alzheimer’s: From Regress to Progress” has revealed that in the last decade up to 100 treatments and solutions have failed to be approved by medical authorities or to reach patients. During the same period there have been only three medicines that have been approved to treat Alzheimer’s symptoms, but not the conditions itself. This 30 to 1 ratio of setbacks to solutions indicates the problem with elaborating efficient solutions.
“The obstacles facing Alzheimer’s research are disappointing for both medical professionals as well as for the patients and their families; however these setbacks are a vital step forward towards better comprehending this problematic neurological condition,” said Dr. Pietsch. “The fact of the matter is that while we can regard these setbacks in the development of efficient Alzheimer’s solutions and treatments as failures they actually assist us in guiding research in the right direction by providing us with critical information that enable science to advance.”
As specified in “The Future of Alzheimer’s Treatment” study, companies in the biopharmaceutical and biotechnology research industries are actively examining and creating new medicines and technologies for patients affected by the disease and a number of other dementias, which includes among others a patent-pending device implanted in the omentum, a protective layer of skin that secures the abdominal organs which, once stimulated, has been confirmed to improve cognitive functions in the case of a number of degenerative neurological diseases.
“In order for such vital and innovative work to progress and to alleviate the expensive impact of this condition on our healthcare system, policymakers need to support approaches and policies that promote medical developments and embrace growth drivers like the biopharmaceutical and biotechnology sectors,” concluded Mr. Pietsch.
About Braincure Biotech
Braincure Biotech is an innovative company specialized in biotechnology as well as biopharmaceuticals, committed to pursuing the development of original treatment procedures with the aim of combating dementias, with an emphasis on Alzheimer’s disease. We possess one of the most extensive international pipelines for the treatment of Alzheimer’s and also a comprehensive strategy to product growth.
Address: Taipei Far Eastern Plaza, No. 207, Section 2, Dun Hua South Road, Taipei 106, Taiwan (R.O.C.).
contact@braincure-biotech.com
http://www.braincure-biotech.com
Contact
BrainCure Biotech
Anders Frohlond
+866 224659909
www.braincure-biotech.com
Anders Frohlond
+866 224659909
www.braincure-biotech.com
Contact
Categories